Fumed Silica 380 m²/g: Properties, Thickening Performance and Applications

Published: Source: Silica Raw Materials News Section: Silica Raw Materials

📌 Key Takeaways

  • Topic: Colloidal Silica Slurry: Specifications and Uses in CMP and Precision Polishing
  • Keywords: fumed silica manufacturer
  • Published: 2026-11-20 04:14:27
  • Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.

Spherical vs Angular Silica: Which Filler Performs Better and When?

Tosoh Silica: Product Range, Applications and Key Grades
Zhang, Q., Li, X., Peng, L., Zou, X. & Zhao, Y. Porous silica nanoparticles capped with polyethylenimine/green carbon dots for pH/redox responsive drug release. Inorg. Chem. Commun. 123, 108340 (2021). Article CAS Google Scholar
SiO₂ Explained: Chemical Formula, Structure, Properties and Applications of Silicon Dioxide
Wang, S. J. et al. Biomimetic nanosilica-collagen scaffolds for in situ bone regeneration: toward a cell‐free, one‐step surgery. Adv. Mater. 31, 1904341 (2019). Post CAS Google Scholar
Pharmaceutical Grade Silica: Specifications, USP/EP Standards and Uses as an Excipient
Silica for Adhesives: Thickening, Thixotropy and Reinforcement Explained
Targeted delivery tactics are generally divided into two categories: passive targeting and active targeting. Passive targeting relies on the pathological qualities of the disease microenvironment and the nature of the drug delivery system itself, which allows the drug to effectively accumulate at the lesion site of disease. The most well-known passive targeting is the EPR effect of tumor, which refers to the phenomenon that some particles with particular size (20-200 nm) penetrate more without difficulty into tumor tissue and remain there for a long time when compared to normal tissue. 316, 317 Therefore, controlling the size of MSNs to a fitting range will facilitate their enrichment in the tumor sites. However, it has also been highlighted that the passive targeting strategy relying on the EPR effect can attain only 0.7% of the injected NPs enrichment in solid tumors, 318 which will not be handy for the clinical translation of nanotechnology. In contrast, active targeting relies on the active recognition between the molecules on the NPs surface and the specific molecules or proteins in the illness microenvironment, which is also referred to as ligand-receptor specific binding. 319 The active targeting shows a higher drug delivery efficiency compared to passive targeting. 320 Targeted ligands, such as proteins, antibodies, peptides, nucleic acids and chemical tiny molecules, can be modified on the surface of MSNs, and the modified MSNs are capable of selectively aggregating at the lesion site based on the powerful affinity between the targeted ligands and the particular receptors overexpressed in the sickness microenvironment. 321, 322, 323, 324 For instance, compared to mature vascular endothelial cells, tumor neovascular endothelial cells are highly expressed in an array of proteins, such as integrins, transmembrane glycoproteins and aminopeptidase N. Molecules that recognize these highly expressed proteins can be used for neovascular-based targeted drug delivery. A standard example is that arginylglycylaspartic acid (RGD)-modified MSNs can selectively bind integrin α ν β 3 receptor and hence be applied to target tumor neovascularization. 325

U.S. Silica: Company Overview, Products and Markets Served

What is silica (SiO₂)?

silicon dioxide in food

What is the difference between fumed silica and precipitated silica?

silica gel desiccant

What drives silica raw material prices?

silicon dioxide CAS 7631-86-9 MSNs-based nanocomposites

Cite this article: Silica Raw Materials News. "Fused Silica Powder Supplier: Purity, Particle Size Options and Selection Tips ." Published 2026-11-20 04:14:27. /news/article.html
Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.